Performance of a multi-cancer early detection test in the randomized controlled NHS-Galleri trial.

The multi-cancer early detection test in the NHS-Galleri trial detected primary cancers in 0.40% to 0.60% of participants across three screening rounds.

• Why it matters: Understanding the test’s performance in population screening is crucial for evaluating its potential to improve early cancer detection and inform healthcare strategies within NHS settings.
• What they did: The study analyzed 142,250 participants aged 50-77 years over three annual screening rounds, reporting on positive test rates, predictive values, specificity, sensitivity, and CSO accuracy without hypothesis testing.
• The result: The test showed positive predictive values between 45.8% and 58.0%, specificity from 99.50% to 99.60%, and episode sensitivity from 26.7% to 37.2% for all cancers, indicating its potential utility and limitations in population screening.